3.4.21.B39 ascites fluid from ovarian cancer patients 647355 3.4.21.B39 bone marrow expression 670978 3.4.21.B39 bone marrow low expression 670977 3.4.21.B39 brain - 647353 3.4.21.B39 brain high expression level 647332 3.4.21.B39 brain lexpression 670978 3.4.21.B39 breast - 680680 3.4.21.B39 breast expression levels of KLK5 and KLK7 in benign breast tissues and metastases, and the relationship between KLK5 and KLK7 expression and and clinicopathological factors. mRNA levels of KLK5 and KLK7 in normal breast tissues, benign breast tissues, primary tumors, and lymph node metastases, overview. mRNA levels of KLK5 and KLK7 are both downregulated in breast cancers relative to normal and benign tissues, and downregulated in metastases compared to primary cancers 707996 3.4.21.B39 breast high expression 670978 3.4.21.B39 breast high expression level 647332 3.4.21.B39 breast cancer cell expression levels of KLK5 and KLK7 in benign breast tissues and metastases, and the relationship between KLK5 and KLK7 expression and and clinicopathological factors. mRNA levels of KLK5 and KLK7 in normal breast tissues, benign breast tissues, primary tumors, and lymph node metastases, overview. mRNA levels of KLK5 and KLK7 are both downregulated in breast cancers relative to normal and benign tissues, and downregulated in metastases compared to primary cancers 707996 3.4.21.B39 breast cancer cell no expression 670978 3.4.21.B39 breast cancer cell line high expression 670977 3.4.21.B39 breast cancer cell line no expression 670978 3.4.21.B39 cervicovaginal fluid level of KLK 5 peaks around 4 days post ovulation 691151 3.4.21.B39 DU-145 cell - 707624 3.4.21.B39 EJ-1 cell - 679041 3.4.21.B39 epidermis - 647353, 665944, 681834, 732104 3.4.21.B39 epidermis interfollicular epidermis 647354 3.4.21.B39 epithelium of plantar skin 647353 3.4.21.B39 granular cell - 732104 3.4.21.B39 HaCaT cell - 717412 3.4.21.B39 hair follicle interfollicular epidermis 647354 3.4.21.B39 hair follicle terminal 647354 3.4.21.B39 keratinocyte - 647353, 681834 3.4.21.B39 keratinocyte cell line pre-malignant keratinocyte cell line 717868 3.4.21.B39 kidney - 647353 3.4.21.B39 kidney expression 670978 3.4.21.B39 kidney high expression 670977 3.4.21.B39 KK-47 cell - 679041 3.4.21.B39 KU-1 cell - 679041 3.4.21.B39 KU-7 cell - 679041 3.4.21.B39 liver expression 670978 3.4.21.B39 liver low expression 670977 3.4.21.B39 mammary gland high expression 670977 3.4.21.B39 milk - 647355 3.4.21.B39 NKB-1 cell - 679041 3.4.21.B39 OKF-6 cell - 717868 3.4.21.B39 oral squamous cell carcinoma cell - 717868 3.4.21.B39 oral squamous cell carcinoma cell kallikreins 5, 7, 8, and 10 are abundantly expressed in human oral squamous cell carcinoma and may be implicated in malignant progression 692566 3.4.21.B39 ovarian carcinoma cell gene overexpression in a subset of more aggressive ovarian tumors 647332 3.4.21.B39 ovary low expression 670977 3.4.21.B39 ovary cancer cell expression 670978 3.4.21.B39 ovary cancer cell high expression 670977 3.4.21.B39 ovary cancer cell line high expression 670978 3.4.21.B39 pancreatic cancer cell line high expression 670977 3.4.21.B39 placenta - 647353 3.4.21.B39 placenta low expression 670977 3.4.21.B39 prostate - 647332 3.4.21.B39 prostate specimens from patients with benign prostatic hyperplasia (BPH) show higher levels of KLK5 mRNA expression than those from patients with prostate cancer 691861 3.4.21.B39 prostate cancer cell - 707624 3.4.21.B39 prostate cancer cell line - 707624 3.4.21.B39 prostate cancer cell line high expression 670977 3.4.21.B39 prostate gland - 669444 3.4.21.B39 prostate gland low expression 670977 3.4.21.B39 renal cell carcinoma cell decreased immunohistochemical expression compared to normal cells 670981 3.4.21.B39 saliva KLK5 peaks slightly at mid-cycle and shows a major peak at day 25 of menstrual cycle 691151 3.4.21.B39 salivary gland - 647332 3.4.21.B39 salivary gland high expression 670977, 670978 3.4.21.B39 SCC-25 cell - 717868 3.4.21.B39 sebaceous follicle - 647354 3.4.21.B39 serum female and male 647355 3.4.21.B39 skin - 647353, 680225, 680680, 681454, 709319, 753511 3.4.21.B39 skin high expression 670977 3.4.21.B39 skin high expression level 647332 3.4.21.B39 skin kallikrein-related peptidase 5 is a major serine protease found in the skin, which is secreted from lamellar granules following its expression in the stratum granulosum and activated in the extracellular space of the stratum corneum 732104 3.4.21.B39 skin substructure distribution 647354 3.4.21.B39 SNK-57 cell - 679041 3.4.21.B39 spleen expression 670978 3.4.21.B39 stratum corneum - 647353, 669753, 680225, 691153, 753884 3.4.21.B39 stratum corneum plantar 647354 3.4.21.B39 stratum granulosum enzyme expression 732104 3.4.21.B39 sweat - 669753 3.4.21.B39 T-24 cell - 679041 3.4.21.B39 testis - 680680 3.4.21.B39 testis expression 670978 3.4.21.B39 testis high expression level 647332 3.4.21.B39 testis low expression 670977 3.4.21.B39 thymus - 647332 3.4.21.B39 thymus expression 670978 3.4.21.B39 thymus low expression 670977 3.4.21.B39 thyroid gland - 647332 3.4.21.B39 thyroid gland expression 670978 3.4.21.B39 trachea - 647332 3.4.21.B39 trachea high expression 670978 3.4.21.B39 trachea low expression 670977 3.4.21.B39 urinary bladder carcinoma cell line - 679041 3.4.21.B39 uterus expression 670978 3.4.21.B39 uterus low expression 670977 3.4.21.B39 vagina expression 670978 3.4.21.B39 vagina high expression 670977